论文部分内容阅读
目的：探讨多药耐药相关蛋白（ＭＲＰ）在胃癌和肾癌中表达的临床意义。方法：应用免疫组化ＬＳＡＢ法检测５２例胃癌和２０例肾癌组织中ＭＲＰ表达。结果：ＭＲＰ在胃癌中阳性表达率为３８．５％（２０／５２），肾癌为６０％（１２／２０），ＭＲＰ在肿瘤细胞膜上和胞浆内均见表达，但以胞浆（粗颗粒状）更显著。晚期胃癌和肾癌（ＩＩ、Ⅳ期）阳性表达率分别为６０％（１５／２５）和８８．９％（８／９），高于Ｉ、ＩＩ期患者（１８．５％与３６．４％，均分别Ｐ＜０．０１和Ｐ＜０．０５）。且胃癌患者ＭＲＰ阳性表达者的平均存活期和五年生存率显著低于阴性者。结论：ＭＲＰ表达与胃癌和肾癌的浸润转移相关，并可能是两者内源性耐药的重要机制
Objective: To explore the clinical significance of multidrug resistance-associated protein (MRP) expression in gastric and renal cancer. Methods: The expression of MRP was detected in 52 cases of gastric cancer and 20 cases of renal cell carcinoma by immunohistochemical LSAB method. Results: The positive expression rate of MRP in gastric carcinoma was 38.5% (20/52) and in renal carcinoma was 60% (12/20). MRP was expressed on both the tumor cell membrane and cytoplasm, but cytoplasm (coarse Granular) is more pronounced. The positive expression rates of advanced gastric cancer and renal cancer (stages II and IV) were 60% (15/25) and 88.9% (8/9), respectively, higher than those of stage I and II patients (18.5% and 36.4) %, both P <0.01 and P <0.05). The average survival and five-year survival rate of MRP positive expression in gastric cancer patients were significantly lower than those in negative patients. Conclusion: MRP expression is associated with infiltration and metastasis of gastric and renal cancer, and may be an important mechanism of both endogenous drug resistance.